The report highlights Daiichi Sankyo Group's commitment to becoming a ""Global Pharma Innovator with competitive advantage in oncology."" It details the company's progress towards this vision, including the launch of new oncology products and the establishment of strategic alliances. The report also outlines the company's initiatives for sustainability, including environmental management, compliance, and access to healthcare. It includes a materiality assessment and a matrix, and it is assured by KPMG AZSA Sustainability Co., Ltd.
Issuing Company Daiichi Sankyo Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 6.76 MB
No. of Pages 59 pages
Reporting periodApril 1, 2018-March 31, 2019
Report EditionUnknown
Assurance Provider KPMG AZSA Sustainability Co., Ltd.
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue